Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague

Claire A. Cornelius, Lauriane E. Quenee, Katie A. Overheim, Frederick Koster, Trevor L. Brasel, Derek Elli, Nancy A. Ciletti, Olaf Schneewind

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Vaccine and therapeutic strategies that prevent infections with Yersinia pestis have been sought for over a century. Immunization with live attenuated (nonpigmented) strains and immunization with subunit vaccines containing recombinant low-calcium-response V antigen (rLcrV) and recombinant F1 (rF1) antigens are considered effective in animal models. Current antiplague subunit vaccines in development for utilization in humans contain both antigens, either as equal concentrations of the two components (rF1 plus rLcrV) or as a fusion protein (rF1-rLcrV). Here, we show that immunization with either purified rLcrV (a protein at the tip of type III needles) or a variant of this protein, recombinant V10 (rV10) (lacking amino acid residues 271 to 300), alone or in combination with rF1, prevented pneumonic lesions and disease pathogenesis. In addition, passive immunization studies showed that specific antibodies of macaques immunized with rLcrV, rV10, or rF1, either alone or in combination, conferred protection against bubonic plague challenge in mice. Finally, we found that when we compared the reactivities of anti-rLcrV and anti-rV10 immune sera from cynomolgus macaques, BALB/c mice, and brown Norway rats with LcrV-derived peptides, rV10, but not rLcrV immune sera, lacked antibodies recognizing linear LcrV oligopeptides.

Original languageEnglish (US)
Pages (from-to)5588-5597
Number of pages10
JournalInfection and Immunity
Volume76
Issue number12
DOIs
StatePublished - Dec 2008
Externally publishedYes

Fingerprint

Plague
Macaca
Immunization
Antigens
Calcium
Subunit Vaccines
Immune Sera
Recombinant Fusion Proteins
Yersinia pestis
Oligopeptides
Passive Immunization
Antibodies
Recombinant Proteins
Lung Diseases
Needles
Vaccines
Animal Models
Amino Acids
Peptides

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Parasitology
  • Infectious Diseases

Cite this

Cornelius, C. A., Quenee, L. E., Overheim, K. A., Koster, F., Brasel, T. L., Elli, D., ... Schneewind, O. (2008). Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infection and Immunity, 76(12), 5588-5597. https://doi.org/10.1128/IAI.00699-08

Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. / Cornelius, Claire A.; Quenee, Lauriane E.; Overheim, Katie A.; Koster, Frederick; Brasel, Trevor L.; Elli, Derek; Ciletti, Nancy A.; Schneewind, Olaf.

In: Infection and Immunity, Vol. 76, No. 12, 12.2008, p. 5588-5597.

Research output: Contribution to journalArticle

Cornelius, CA, Quenee, LE, Overheim, KA, Koster, F, Brasel, TL, Elli, D, Ciletti, NA & Schneewind, O 2008, 'Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague', Infection and Immunity, vol. 76, no. 12, pp. 5588-5597. https://doi.org/10.1128/IAI.00699-08
Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel TL, Elli D et al. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infection and Immunity. 2008 Dec;76(12):5588-5597. https://doi.org/10.1128/IAI.00699-08
Cornelius, Claire A. ; Quenee, Lauriane E. ; Overheim, Katie A. ; Koster, Frederick ; Brasel, Trevor L. ; Elli, Derek ; Ciletti, Nancy A. ; Schneewind, Olaf. / Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. In: Infection and Immunity. 2008 ; Vol. 76, No. 12. pp. 5588-5597.
@article{de86eee6b9f44f7bab042c3fe7997f99,
title = "Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague",
abstract = "Vaccine and therapeutic strategies that prevent infections with Yersinia pestis have been sought for over a century. Immunization with live attenuated (nonpigmented) strains and immunization with subunit vaccines containing recombinant low-calcium-response V antigen (rLcrV) and recombinant F1 (rF1) antigens are considered effective in animal models. Current antiplague subunit vaccines in development for utilization in humans contain both antigens, either as equal concentrations of the two components (rF1 plus rLcrV) or as a fusion protein (rF1-rLcrV). Here, we show that immunization with either purified rLcrV (a protein at the tip of type III needles) or a variant of this protein, recombinant V10 (rV10) (lacking amino acid residues 271 to 300), alone or in combination with rF1, prevented pneumonic lesions and disease pathogenesis. In addition, passive immunization studies showed that specific antibodies of macaques immunized with rLcrV, rV10, or rF1, either alone or in combination, conferred protection against bubonic plague challenge in mice. Finally, we found that when we compared the reactivities of anti-rLcrV and anti-rV10 immune sera from cynomolgus macaques, BALB/c mice, and brown Norway rats with LcrV-derived peptides, rV10, but not rLcrV immune sera, lacked antibodies recognizing linear LcrV oligopeptides.",
author = "Cornelius, {Claire A.} and Quenee, {Lauriane E.} and Overheim, {Katie A.} and Frederick Koster and Brasel, {Trevor L.} and Derek Elli and Ciletti, {Nancy A.} and Olaf Schneewind",
year = "2008",
month = "12",
doi = "10.1128/IAI.00699-08",
language = "English (US)",
volume = "76",
pages = "5588--5597",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague

AU - Cornelius, Claire A.

AU - Quenee, Lauriane E.

AU - Overheim, Katie A.

AU - Koster, Frederick

AU - Brasel, Trevor L.

AU - Elli, Derek

AU - Ciletti, Nancy A.

AU - Schneewind, Olaf

PY - 2008/12

Y1 - 2008/12

N2 - Vaccine and therapeutic strategies that prevent infections with Yersinia pestis have been sought for over a century. Immunization with live attenuated (nonpigmented) strains and immunization with subunit vaccines containing recombinant low-calcium-response V antigen (rLcrV) and recombinant F1 (rF1) antigens are considered effective in animal models. Current antiplague subunit vaccines in development for utilization in humans contain both antigens, either as equal concentrations of the two components (rF1 plus rLcrV) or as a fusion protein (rF1-rLcrV). Here, we show that immunization with either purified rLcrV (a protein at the tip of type III needles) or a variant of this protein, recombinant V10 (rV10) (lacking amino acid residues 271 to 300), alone or in combination with rF1, prevented pneumonic lesions and disease pathogenesis. In addition, passive immunization studies showed that specific antibodies of macaques immunized with rLcrV, rV10, or rF1, either alone or in combination, conferred protection against bubonic plague challenge in mice. Finally, we found that when we compared the reactivities of anti-rLcrV and anti-rV10 immune sera from cynomolgus macaques, BALB/c mice, and brown Norway rats with LcrV-derived peptides, rV10, but not rLcrV immune sera, lacked antibodies recognizing linear LcrV oligopeptides.

AB - Vaccine and therapeutic strategies that prevent infections with Yersinia pestis have been sought for over a century. Immunization with live attenuated (nonpigmented) strains and immunization with subunit vaccines containing recombinant low-calcium-response V antigen (rLcrV) and recombinant F1 (rF1) antigens are considered effective in animal models. Current antiplague subunit vaccines in development for utilization in humans contain both antigens, either as equal concentrations of the two components (rF1 plus rLcrV) or as a fusion protein (rF1-rLcrV). Here, we show that immunization with either purified rLcrV (a protein at the tip of type III needles) or a variant of this protein, recombinant V10 (rV10) (lacking amino acid residues 271 to 300), alone or in combination with rF1, prevented pneumonic lesions and disease pathogenesis. In addition, passive immunization studies showed that specific antibodies of macaques immunized with rLcrV, rV10, or rF1, either alone or in combination, conferred protection against bubonic plague challenge in mice. Finally, we found that when we compared the reactivities of anti-rLcrV and anti-rV10 immune sera from cynomolgus macaques, BALB/c mice, and brown Norway rats with LcrV-derived peptides, rV10, but not rLcrV immune sera, lacked antibodies recognizing linear LcrV oligopeptides.

UR - http://www.scopus.com/inward/record.url?scp=57349127240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349127240&partnerID=8YFLogxK

U2 - 10.1128/IAI.00699-08

DO - 10.1128/IAI.00699-08

M3 - Article

C2 - 18794281

AN - SCOPUS:57349127240

VL - 76

SP - 5588

EP - 5597

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 12

ER -